Compare · NVO vs PLRZ
NVO vs PLRZ
Side-by-side comparison of Novo Nordisk A/S (NVO) and Polyrizon Ltd. (PLRZ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PLRZ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 7888.7x PLRZ ($24.3M).
- Over the past year, NVO is down 45.4% and PLRZ is up 167.1% - PLRZ leads by 212.4 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 3 for PLRZ).
- NVO has more recent analyst coverage (25 ratings vs 0 for PLRZ).
- Company
- Novo Nordisk A/S
- Polyrizon Ltd.
- Price
- $41.26-3.91%
- $13.22+1.07%
- Market cap
- $191.82B
- $24.3M
- 1M return
- -9.94%
- -9.95%
- 1Y return
- -45.36%
- +167.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 8
- 3
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest PLRZ
- Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial
- SEC Form 6-K filed by Polyrizon Ltd.
- SEC Form 6-K filed by Polyrizon Ltd.
- SEC Form 6-K filed by Polyrizon Ltd.
- Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial
- Pulse Equity: Emerging Outbreaks - Polyrizon's Approach to Broad and Rapidly Deployable Protection
- SEC Form EFFECT filed by Polyrizon Ltd.
- SEC Form 6-K filed by Polyrizon Ltd.
- Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform
- Amendment: SEC Form F-1/A filed by Polyrizon Ltd.